ENDPOINTS NEWS55m
Re­gor’s obe­si­ty pill posts mut­ed weight loss in Phase 2a, en­ters new tri­al
Regor Therapeutics' oral obesity drug RGT-075 shows 5% weight loss at 12 weeks in Phase 2a, trailing incretin pills from ...
ENDPOINTS NEWS4h
Bay­er’s Blue­Rock now plans to bring Parkin­son’s cell ther­a­py straight to Phase 3 tri­al
Bayer's experimental Parkinson’s disease therapy made from stem cells will soon enter late-stage studies, marking a key test ...
ENDPOINTS NEWS5h
GSK kicks off JPM deal­mak­ing with $1B+ buy­out of IDRx and its rare can­cer drug
Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held ...
ENDPOINTS NEWS6h
Lan­theus to buy Life Mol­e­c­u­lar Imag­ing for $350M, net­ting Alzheimer's di­ag­nos­tic
Radiopharmaceutical maker Lantheus Holdings plans to acquire Life Molecular Imaging for $350 million in a bid to build up its ...
ENDPOINTS NEWS13h
Break­ing: J&J looks at po­ten­tial bid for In­tra-Cel­lu­lar — re­port
Johnson & Johnson is considering an acquisition of CNS drugmaker Intra-Cellular Therapies, according to anonymous sources ...
ENDPOINTS NEWS12h
Ex­clu­sive: Buck­ing gene edit­ing down­turn, Tune rais­es $175M to bring epi­ge­net­ic edit­ing to clin­ic
Tune Therapeutics raises $175M Series B for epigenetic editing, with hepatitis B drug Tune-401 in the clinic. NEA, Yosemite, ...